Thursday, The FDA decided the scarcity of Eli Lilly And Co’s LLY tirzepatide injection, a glucagon-like peptide 1 (GLP-1) treatment, has been resolved.
Tirzepatide injection, branded as Mounjaro and Zepbound, has been in scarcity since 2022 because of elevated demand.
The U.S. well being regulator reminded compounders of the authorized restrictions on making copies of FDA-approved medication.
The FDA famous that Novo Nordisk A/S‘ NVO semaglutide (Wegovy, Ozempic) continues to be in scarcity.
Regardless of semaglutide being the lively ingredient in Hims & Hers Well being Inc’s HIMS compounded GLP-1 product, a Truist analyst notes that the current FDA commentary has reignited investor issues concerning the long-term viability of compounded GLP-1 remedies as soon as the availability scarcity ends.
Truist’s client survey reveals that roughly 10% of shoppers at present use compounded GLP-1 medicines, whereas 14% are on branded variations.
Additionally Learn: Hims & Hers To Supply Entry To Compounded Diabetes And Weight Loss Medication For Simply $99/Month To Sure Skilled Personnel.
Many individuals choosing compounded GLP-1s cite decrease prices as the principle purpose, whereas others notice that their main care physicians are hesitant to prescribe the branded variations.
Hims & Hers Well being’s assertion that demand for its weight reduction service might stay robust, even after provide shortages ease, so long as the corporate operates inside compounding laws and respects branded drug patents.
Primarily based on third-quarter card knowledge evaluation, the analyst notes that Hims & Hers Well being’s Q3 2024 income is predicted to exceed the corporate’s steerage vary of $375 million to $380 million by roughly $5 million to $10 million.
The analyst additionally highlights that Hims & Hers Well being’s common transaction value was up 14% sequentially at $126.9 vs. ~$111 within the second quarter of 2024. Web orders for 3Q24 elevated 3% sequentially from 2Q24.
Truist maintains a Maintain ranking for Hims & Hers Well being with a value goal of $23.
Worth Motion: HIMS inventory is up 0.18% at $17.16 on the final examine Friday.
Learn Subsequent:
Photograph by Vidmir Rais through Pixabay
Market Information and Information delivered to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
